SkinStylus® is 3 times as efficient as SkinPen®, RejuvaPen NXT®, and Exceed® because it has 3 cartridge configurations instead of 1
You will never speak to a sales rep. In fact, SkinStylus® costs 30% less than other options because we cut out all sales reps and middlemen. Book your call now and speak only with Kristin Groop, 30-year clinician and co-inventor of the SkinStylus® Microneedling System.
The SkinStylus SteriLock® MicroSystem is the only system cleared by the FDA to be used on all six skin types.
Unlike laser, IPL, and chemical peels, SkinStylus® MicroSystems can be used on all skin types without fear of hypopigmentation, hyperpigmention, burning, and most importantly, recent mild to moderate sun exposure.
SkinStylus® is “a masterpiece of American ingenuity”, with Class II clearance and clinical data on file with FDA.gov.
12 pin, 36 pin, and 36 pin HiLo technology is not available in any other system.
|FDA cleared to 2.5 mm|
|12 pin, 36 pin, and 36 pin HiLo technology|
|Three different FDA cleared cartridge configurations for maximum flexibility|
|Can either be intermediate disinfected or autoclave reprocessed without need for sheath|
|FDA cleared with both battery (cordless) and corded power options|
|FDA cleared with a TWO YEAR Warranty|
|Patented Seven-Step Safety System that prevents cross-contamination|
|Cartridges utilize gamma ray sterilization|
SkinStylus® includes a Three Year Warranty depending on the selected package.
Both corded and cordless options are available.
Two removable nose cones can be reprocessed in an autoclave.
14 hours of research supported video education available upon purchase of your new SkinStylus®.
Schedule a call with a 21-year clinician now.
Never speak to a sales rep.
The SkinStylus SteriLock® MicroSystem has been cleared by the FDA as a Class II Medical Device for the indication of treating abdominal scars (such as tummy tuck scars) to 2.5 mm, in adults over 22 years old. In a controlled clinical trial, 2 out of 3 physician graders observed a clinically meaningful improvement in 22 out of 30 subjects (73%). Clinical data on file.